Etanercept attenuates traumatic brain injury in rats by reducing early microglial expression of tumor necrosis factor-α
- Chung-Ching Chio†1,
- Chin-Hong Chang†1,
- Che-Chuan Wang1,
- Chong-Un Cheong2,
- Chien-Ming Chao3,
- Bor-Chih Cheng1, 5,
- Chung-Zhing Yang5 and
- Ching-Ping Chang4Email author
© Chio et al.; licensee BioMed Central Ltd. 2013
Received: 8 November 2012
Accepted: 7 March 2013
Published: 15 March 2013
Tumor necrosis factor-alpha (TNF-α) is elevated early in injured brain after traumatic brain injury (TBI), in humans and in animals. Etanercept (a TNF-α antagonist with anti-inflammatory effects) attenuates TBI in rats by reducing both microglial and astrocytic activation and increased serum levels of TNF-α. However, it is not known whether etanercept improves outcomes of TBI by attenuating microglia-associated, astrocytes-associated, and/or neurons-associated TNF-α expression in ischemic brain. A well clinically relevant rat model, where a lateral fluid percussion is combined with systemic administration of etanercept immediately after TBI, was used. The neurological severity score and motor function was measured on all rats preinjury and on day 3 after etanercept administration. At the same time, the neuronal and glial production of TNF-α was measured by Immunofluorescence staining. In addition, TNFα contents of ischemic cerebral homogenates was measured using commercial enzyme-linked immunosorbent assay kits.
In addition to inducing brain ischemia as well as neurological and motor deficits, TBI caused significantly higher numbers of microglia-TNF-α double positive cells, but not neurons-TNF-α or astrocytes-TNF-α double positive cells in the injured brain areas than did the sham operated controls, when evaluated 3 days after TBI. The TBI-induced cerebral ischemia, neurological motor deficits, and increased numbers of microglia-TNF-α double positive cells and increased TNF-α levels in the injured brain were all significantly attenuated by etanercept therapy.
This finding indicates that early microglia overproduction of TNF-α in the injured brain region after TBI contributes to cerebral ischemia and neurological motor deficits, which can be attenuated by etanercept therapy. Studies in this model could provide insight into the mechanisms underlying neurological motor disturbance in brain-injured patients.
Tumor necrosis factor-alpha (TNF-α) is elevated in both the serum and cerebrospinal fluid of humans after traumatic brain injury (TBI) [1, 2]. It is also elevated 1 to 4 hours after injury in clinically relevant models of TBI such as lateral fluid-percussion injury (FPI) [3–5]. The overproduction of TNF-α caused by TBI can be significantly attenuated by blockade of TNF-α synthesis or activity [6–8]. However, the cellular sources of this early elevation of TNF-α remain unclear. Evidence has indicated that TNF-α is predominantly expressed by neurons  or microglia [9, 10] in the injured brain.
Etanercept is a TNF antagonist with anti-inflammatory effects. Systemic administration at the dosage of 5 mg/kg of body weight improves outcomes of TBI in rats by reducing microglial and astrocytic activation and activated inflammation (e.g., increased serum levels of TNF-α) . Again, it is not known whether etanercept improves outcomes of TBI in rats by reducing microglia-associated, astrocytes-associated and/or neurons-associated TNF-α expression in ischemic brain.
We explored these two questions by studying the interrelationship between the activation of microglia-TNF-α, astrocyte-TNF-α, and neuron-TNF-α double labeling cells in the ischemic brain areas and the development of cerebral ischemia and neurological and motor dysfunction as well as the attenuating of cerebral ischemia and neurological and motor dysfunction by etanercept therapy after TBI.
Male Sprague–Dawley rats (280–300 g), obtained from the Animal Resource Center of the Taiwan National Science Council, were housed four per group at an ambient temperature of 22 ± 1°C with a 12-h light–dark cycle. Pelleted rat chow and tap water were available ad libitum. All protocols, designed to minimize discomfort in the animals during surgery and in the recovery period, were approved by the Institutional Animal Care and Use Committee of Southern Taiwan University of Science and Technology.
The rats were anesthetized with sodium pentobarbital (25 mg/kg, intraperitoneally [i.p.]; Sigma Chemical, St. Louis, MO, USA) and a mixture containing ketamine (4.4 mg/ kg, intramuscularly [i.m.]; Nankuang Pharmaceutical, Tainan, Taiwan), atropine (0.02633 mg/kg, [i.m.]; Sintong Chemical, Taoyuan City, Taiwan), and xylazine (6.77 mg/kg, [i.m.]) (Bayer AG, Leverkusen, Germany). Both the femoral artery and vein on the right side were cannulated with PE50 polyethylene tubing to monitor blood pressure and analyze blood gas respectively. After cannulation, the wound was sutured and the rats were placed in a stereotaxic frame. Each rat’s scalp was sagittally incised, and then the rat was subjected to a FPI [11, 12]. Prior to FPI, a 4.8-mm circular craniotomy was performed midway between the lambda and bregma skull points 3.0 mm to the right of the central suture. A modified Luer-Lock connector (trauma cannula) (2.6 mm inner diameter) was secured into the craniotomy with cyanoacrylate adhesive and dental acrylic. Subsequently, the FPI was induced by a pressure (severe intensity: amplitude of 2.2 atm ospheres) delivered by a fluid percussion device (Virginia Commonwealth University Biochemical Engineering, Richmond, VA, USA). The rat was removed from the device with the acrylic removed, and the incision sutured. Each injured and sham-injured animal for the FPI model was housed individually and closely evaluated for behavioral recovery immediately after the FPI. During the surgical procedure, mean arterial pressure, heart rate, and core temperature were continuously monitored for indicating depth of anesthesia.
The rats (n=96) were randomly allocated into the following groups: 1) FPI+saline control group (n=32): rats were subjected to FPI plus a dose of normal saline (1 ml/kg body weight [i.p.]) once every 12 h for 3 consecutive days ; 2) FPI+etanercept group (n = 32): this group was subjected to FPI plus etanercept (5 mg/kg body weight [i.p.]) once per 12 h for 3 consecutive days; and 3) untreated Sham group (n = 32): rats were subjected to the same surgical procedures as the other two groups, but were not given a FPI. The injection volume was the same for both saline and etanercept groups. The sham-group was untreated.
In experiment 1, etanercept (5 mg/kg [i.p.]) (n=8) or saline (1 ml/kg [i.p.]) (n=8) was randomly administrated immediately after FPI, and their effects on neurological motor performance were assessed preinjury and on 4 days post-FPI. Another 8 untreated sham-operated rats were used as controls. Etanercept (ENBREL™ Wyeth Laboratories, Hampshire, UK) was reconstituted with normal saline according to the manufacturer’s instructions.
In experiment 2, three days after FPI, immediately following the neurological motor tests, all the rats used in experimental 1 were killed 3 days after FPI for brain contusion assessment.
In experiment 3, etanercept (5 mg/kg [i.p.] (n=8) or saline (1 ml/kg [i.p.] (n=8) was randomly given to each rat immediately after FPI once every 12 h for 3 consecutive days, and the effect on the number of the co-localization of TNF-α and microglia specific marker cells, TNF-α and neurons specific marker cells, and TNF-α and astrocyte specific marker cells in the cortex, white matter, hippocampus, or hypothalamus was determined. Untreated sham group, FPI+saline group, and FPI-etanercept group were killed 72 h post-FPI (n=8 for each group) for immunohistological evaluation.
In experiment 4, untreated sham group (n=8), FPI+saline group (n=8), and FPI+etanercept group (n=8) animals were killed 72 h post-FPI for determination of TNF-α protein level in ischemic brains.
Neurological function evaluation
Acute neurological injury was assessed in all rats on the day prior to and on 3 days after surgery using a neurological severity score (NSS) . NSS is a composite of the motor (muscle status, abnormal movement), sensory (visual, tactile and proprioceptive) and reflex tests. One point was given for failure to perform a task. Thus, the higher score, the more severe is injury, with a maximum of 14 points. The NSS was measured on all rats pre injury and on day 3 after etanercept administration.
The inclined plane was used to measure limb strength . The rat was placed, facing right and then left, perpendicular to the slope of a 20×20-cm ruffed surface of an inclined plane starting at an angle of 55°. The angle was increased or decreased in 5° increments to determine the maximal angle at which a rat could hold to the plane. The data for each day were the mean of the left- and right-side maximal angles. All behavioral tests were examined and independently scored by two observers who were unaware of what treatment the rats had been given. These scores were averaged to arrive at one score for each rat for the behavioral session. The rats were tested pre injury and on day 3 after etanercept administration.
TNF-α content of ischemic cerebral homogenate
Cerebral hemispheres were quickly dissected free and kept on ice in physiological salt solution (mM: NaCl 119; KCl 4.7; MgSO4 1.17; KH2PO4 1.18; NaHCO3 25; EDTA 0.026; and CaCl2 2.5) containing 5 mM glucose. Segments of cerebral cortex (75 mg i.e., approximately the weight of each cerebral hemisphere) were weighted, cut into small pieces, dispersed by aspiration into a pipette and suspended in 1 ml of physiological salt solution in a test tube. Samples were kept on wet ice for 20 min before use. The homogenates were centrifuged at 7,500 rpm (5,150×g) for 20 min. The supernatants were used for measuring TNF-α concentrations. TNF-α concentrations were measured using commercial enzyme-linked immunosorbent assay (ELISA) kits (Biosource International Inc. Boshide Company, Wuhan, China) and following the manufacturer’s instructions. The minimum detectable concentrations of TNF-α were 1.1 pg/ml. There was no cross-reactivity reported with other cytokines. All samples were assayed is duplicate.
Cerebral ischemia assay
The triphenyltetrazolium chloride (TTC) staining procedures are described elsewhere . Three days after they had undergone FPI, all the rats were deeply anesthetized (sodium pentobarbital, 100 mg/kg [i.p.]) and then perfused intracardially with saline. Their brain tissue was then removed, immersed in cold saline for 5 min, and sliced into 2.0-mm sections with a tissue slicer. The brain slices were incubated in 2% TTC dissolved in phosphate buffer saline (PBS) for 30 min at 37°C and then transferred to 5% formaldehyde solution for fixation. The volume of ischemia, revealed by negative TTC stains that indicated dehydrogenase-deficient tissue, was measured in each slice and summed using computerized planimetry (PC-based Image Tools Software). The volume of ischemia was calculated as 2 mm (thickness of the slice)×[sum of the ischemia area in all brain slices (mm)2].
Antibodies used for Immunofluorescence staining
Secondary antibody (conjugation)
Mouse IgG (Alexa Fluor 568)
Goat-IgG (DyLight 488)
Images of the fluorescent immunohistochemistry for immune cells were captured at 100x magnification using a fluorescence microscope system (Zeiss Axiovision; Zeiss Gmbh, Göttingen, Germany), and images from bregma −0.8, -1.5, -2.5, -3.0, and −3.5 mm from each animal were evaluated. In each image, immune-positive cells showing staining with a cellular morphology and above background level were manually and exhaustively counted using the Axiovision image analysis software (Zeiss Gmbh), All cell counts were performed by an investigator (C. P.C.) blinded to the treatment status of each animal.
The data are presented as mean ± standard deviation (SD). A repeated measures analysis of variance was used to test the treatment-by-time interactions and the effect of treatment over time on each score. Duncan’s multiple range test was used for post hoc multiple comparisons among means. Analyses for all behavioral variables used Student’s unpaired t-test to compare variables between groups. Bonferroni’s analysis was then performed when appropriate, to determine post-hoc significance at individual time point. Data was analyzed using Statistica, Software® and, in all cases, statistical significance was set at P<0.05.
Acute effects of FPI
The average intensity of the fluid pulse delivered to animals in the injured group was 2.24±0.05 atm (mean±SEM). Immediately following this impact, all rats experienced a period of apnea (lasting approximately 25 sec), hypertension (approximately up to ~140 mmHg and lasting ~25 sec), and tachycardia (~390 beats/min and lasting more than 120 minutes). Sham-injured animals showed no apnea, hypertension, or tachycardia. There was no difference between 2 treatment groups.
FPI caused neurological and motor dysfunction, which etanercept attenuated
FPI induced cerebral ischemia, which etanercept attenuated
TTC staining showed that the (FPI+saline) group had significantly (P<0.001) larger areas of brain ischemia than did the sham-FPI group (Figure 1C). (186±26 mm3 vs 21±5 mm3; n=8 for each group). The cerebral ischemia areas were significantly (P<0.01) smaller in the FPI+etanercept group than in the FPI+saline group (104±12 mm3 vs 186±26 mm3; n=8 for each group) (Figure 1C).
FPI caused the microglial production of TNF-α, which etanercept attenuated
FPI caused overproduction of cerebral TNF-α, which etanercept attenuated
The major findings of our present study are: (1) etanercept injected systemically reduces motor and neurological deficits caused by FPI by day 3 after FPI; (2) the increased numbers of the co-localization of TNF-α and microglia specific marker cells are significantly and selectively higher in the ischemic cortex, white matter, hippocampus, and hypothalamus during FPI which can be attenuated by etanercept therapy; (3) overproduction of cerebral TNF-α in the ischemic cortex caused by FPI can be attenuated by etanercept; (4) by day 3 after FPI, neither the co-localization of TNF-α and astrocyte specific marker cells nor the TNF-α and neuron specific marker cells can be seem in the ischemic brain regions. Our data suggest that systemic administration of etanercept may improve outcome of FPI by attenuating the activation of microglial TNF-α in the ischemic brain. The hypothesis is in part supported by many investigations. For example, Li and Colleagues  has reported that TNF-α is significantly higher in the lesion boundary zone in the saline-treated rats by 3 days after FPI. Cerebral inflammation in response to trauma, stroke, and seizure is characterized by the activation of resident microglia [17–19]. Activated microglia proliferate, change morphology by assuming an amoeboid shape, increase phagocytosis, upregulate MHC class I molecules, and release cytokines [20, 21].
TNF-α transduces death- and survival-signaling through its cognate receptors TNFR1 and TNFR2 and is involved in the inflammatory response following TBI [22–25]. Increases in TNF-α and other cytokines have been reported in cerebrospinal fluid and plasma samples in TBI patients [2, 26–29]. Several groups [3, 5, 30–34] have reported increased TNF-α and other cytokine levels 1 h post-TBI, and peak levels 4 h post-TBI, after which, levels returned toward baseline. In Knoblach et al., , a secondary lesser increase at 72 h post-TBI was also reported. Furthermore, Holmin and Mathiesen  reported persistent elevations 4 days to 3 months after TBI, and Li et al.,  found that TNF-α and other cytokines were significantly higher in the lesion boundary zone in saline-treated TBI rats 3 days post-TBI. In our rat model, microglial overproduction of TNF-α in several ischemic brain regions 3 days after TBI was also reported. In particular, Knoblch et al.  reported peak levels of TNF-α very early after TBI (1–4 hours) with localization to neurons, whereas our present results showed the peak levels of TNF-α occurred at 72 hours and were localized to the microglial cells. Thus, it appears that the cellular sources of this early elevation of TNF-α may be time-dependent. However, the most important point is that this elevated post-TBI TNF-α production in brain tissues can be significantly attenuated by etanercept therapy.
Accumulated evidence shows that TNF-α and its receptor play an important role in the pathophysiology of TBI [22, 24, 25]. In contrast, some evidence suggests that TNF-α plays a neuroprotective role following TBI [35, 36]. Although TNF-α contributes to neuro-anatomical plasticity as well as an improvement of locomotor activity during recovery process , present data indicate that TNF-α is associated with the pathological effects as well as neurological motor deficits during acute phase after TBI. In the present study, despite the etanercept treatment there is still a robust TNF-α release post-injury. However, etanercept should be given only at acute phase [35, 36]. A greater dose of etanercept administered during recovery process would not improve outcome and even exacerbate the pathological effects of TBI.
Etanercept, when administered systemically at the dosage approved for its licensed indications (~50 mg/week in human), would not be expected to achieved therapeutic levels in the cerebrospinal fluid because of its high molecular weight . It should be mentioned that the etanercept doses used in the present set-up are far higher than the normal subcutaneous dose used for rheumatoid arthritis. Administration of a dose in humans might result in significant penetration of etanercept into the cerebrospinal fluid; particularly in an experimental setting such as TBI, in which the blood- cerebrospinal fluid barrier might be damaged.
The present study focuses mainly the effects of etanercept on microglial overproduction of TNF-α in the rat brain effected by TBI. Actually, in addition to TNF-α, TBI-induced increased levels of both interleukin-1β and interleukin-6 were all significantly reduced by etanercept treatment . Additionally, Iba1 stain was chosen as a marker of activated microglia. Stains for surveillance microglia would help clarify if etanercept interferes with microglia activation and/or interferes with chemokines production and subsequent migration of microglia to the contused/ischemic areas of the brain. Furthermore, it is possible that the beneficial effects of etanercept during TBI are a result of limiting macrophage recruitment in part .
It should be mentioned that in the present study, there appears to be quite a few instances of Iba1 and TNF-α labeling that do not coincide and the staining morphology is quite different in some instances (mor elongated Iba1 staining versus round/amoeboid TNF-α staining). Furthermore, Iba1 is not a particularly distinguishing cell-specific marker for microglia in the injured brain as infiltrating macrophages also express this antigen. In addition, although our present study showed that the sham-group displayed no evidence of damage 3 days post-FPI, Jones et al.  did display evidence of damage one month post-FPI. The discrepancy between our results and their findings could be due to time difference.
Finally, it should be mentioned that given that the sham animals in the present study did not receive injections on any treatment the authors might comment on the possible confound that the stress associated with the injections may have had on the TBI group versus sham.
The present study demonstrates that TBI, in addition to inducing cerebral contusion and neurological motor deficits, cause the microglial overproduction of TNF-α in the injured cortex, hippocampus, white matter, and hypothalamus. The TBI-induced neurological motor deficits and microglial overproduction of TNF-α can be significantly attenuated by the post-TBI application of etanercept. Our data identify a role for the microglial production of TNF-α in the outcomes of TBI in rats. Etanercept may attenuate cerebral contusion and neurological motor deficits during TBI by inhibiting the activation of the microglia-TNF-α double positive cells in the ischemic brain region.
This study was funded in part by the Taiwan National Science Council (NSC98-2314-B-218-MY2, NSC99-2314-B-384-004-MY3, NSC100-2314-B-218-001, NSC101-2314-B-218-001-MY3), and the Taiwan Department of Health Center of Excellence for Clinical Trials and Research in Neuroscience (DOH99-TD-B-111-003).
- Goodman JC, Robertson CS, Grossman RG, Narayan RK: Elevation of tumor necrosis factor in head injury. J Neuroimmunol. 1990, 30 (2–3): 213-217.PubMedGoogle Scholar
- Ross SA, Halliday MI, Campbell GC, Byrnes DP, Rowlands BJ: The presence of tumour necrosis factor in CSF and plasma after severe head injury. Br J Neurosurg. 1994, 8 (4): 419-425. 10.3109/02688699408995109.PubMedGoogle Scholar
- Taupin V, Toulmond S, Serrano A, Benavides J, Zavala F: Increase in IL-6, IL-1 and TNF levels in rat brain following traumatic lesion. Influence of pre- and post-traumatic treatment with Ro5 4864, a peripheral-type (p site) benzodiazepine ligand. J Neuroimmunol. 1993, 42 (2): 177-185. 10.1016/0165-5728(93)90008-M.PubMedGoogle Scholar
- Yakovlev AG, Faden AI: Molecular biology of CNS injury. J Neurotrauma. 1995, 12 (5): 767-777. 10.1089/neu.1995.12.767.PubMedGoogle Scholar
- Fan L, Young PR, Barone FC, Feuerstein GZ, Smith DH, McIntosh TK: Experimental brain injury induces differential expression of tumor necrosis factor-alpha mRNA in the CNS. Brain Res Mol Brain Res. 1996, 36 (2): 287-291. 10.1016/0169-328X(95)00274-V.PubMedGoogle Scholar
- Shohami E, Gallily R, Mechoulam R, Bass R, Ben-Hur T: Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol. 1997, 72 (2): 169-177. 10.1016/S0165-5728(96)00181-6.PubMedGoogle Scholar
- Knoblach SM, Faden AI: Interleukin-10 improves outcome and alters proinflammatory cytokine expression after experimental traumatic brain injury. Exp Neurol. 1998, 153 (1): 143-151. 10.1006/exnr.1998.6877.PubMedGoogle Scholar
- Chio CC, Lin JW, Chang MW, Wang CC, Kuo JR, Yang CZ, Chang CP: Therapeutic evaluation of etanercept in a model of traumatic brain injury. J Neurochem. 2010, 115 (4): 921-929. 10.1111/j.1471-4159.2010.06969.x.PubMedGoogle Scholar
- Bezzi P, Volterra A: A neuron-glia signalling network in the active brain. Curr Opin Neurobiol. 2001, 11 (3): 387-394. 10.1016/S0959-4388(00)00223-3.PubMedGoogle Scholar
- Perry SW, Dewhurst S, Bellizzi MJ, Gelbard HA: Tumor necrosis factor-alpha in normal and diseased brain: Conflicting effects via intraneuronal receptor crosstalk?. J Neurovirol. 2002, 8 (6): 611-624. 10.1080/13550280290101021.PubMedGoogle Scholar
- Mclntosh TK, Noble L, Andrews B, Faden AI: Traumatic brain injury in the rat: characterization of a midline fluid-percussion model. Cent Nerv Syst Trauma. 1987, 4: 119-134.Google Scholar
- Jones NC, Cardamone L, Williams JP, Salzberg MR, Myers D, O'Brien TJ: Experimental traumatic brain injury induces a pervasive hyperanxious phenotype in rats. J Neurotrauma. 2008, 25 (11): 1367-1374. 10.1089/neu.2008.0641.PubMedGoogle Scholar
- Shohami E, Novikov M, Bass R: Long-term effect of HU-211, a novel non-competitive NMDA antagonist, on motor and memory functions after closed head injury in the rat. Brain Res. 1995, 674 (1): 55-62. 10.1016/0006-8993(94)01433-I.PubMedGoogle Scholar
- Chang MW, Young MS, Lin MT: An inclined plane system with microcontroller to determine limb motor function of laboratory animals. J Neurosci Methods. 2008, 168 (1): 186-194. 10.1016/j.jneumeth.2007.09.013.PubMedGoogle Scholar
- Wang Y, Lin SZ, Chiou AL, Williams LR, Hoffer BJ: Glial cell line-derived neurotrophic factor protects against ischemia-induced injury in the cerebral cortex. J Neurosci. 1997, 17 (11): 4341-4348.PubMedGoogle Scholar
- Li B, Mahmood A, Lu D, Wu H, Xiong Y, Qu C, Chopp M: Simvastatin attenuates microglial cells and astrocyte activation and decreases interleukin-1beta level after traumatic brain injury. Neurosurgery. 2009, 65 (1): 179-185. 10.1227/01.NEU.0000346272.76537.DC. discussion 185–186PubMedGoogle Scholar
- Dirnagl U, Iadecola C, Moskowitz MA: Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999, 22 (9): 391-397. 10.1016/S0166-2236(99)01401-0.PubMedGoogle Scholar
- Feuerstein G, Wang X, Barone FC: Cytokines in brain ischemia–the role of TNF alpha. Cell Mol Neurobiol. 1998, 18 (6): 695-701. 10.1023/A:1020226020062.PubMedGoogle Scholar
- Minghetti L, Levi G: Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide. Prog Neurobiol. 1998, 54 (1): 99-125. 10.1016/S0301-0082(97)00052-X.PubMedGoogle Scholar
- Batchelor PE, Liberatore GT, Wong JY, Porritt MJ, Frerichs F, Donnan GA, Howells DW: Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J Neurosci. 1999, 19 (5): 1708-1716.PubMedGoogle Scholar
- Hanisch UK: Microglia as a source and target of cytokines. Glia. 2002, 40 (2): 140-155. 10.1002/glia.10161.PubMedGoogle Scholar
- Bermpohl D, You Z, Lo EH, Kim HH, Whalen MJ: TNF alpha and Fas mediate tissue damage and functional outcome after traumatic brain injury in mice. J Cereb Blood Flow Metab. 2007, 27 (11): 1806-1818. 10.1038/sj.jcbfm.9600487.PubMedGoogle Scholar
- Maier B, Lehnert M, Laurer HL, Mautes AE, Steudel WI, Marzi I: Delayed elevation of soluble tumor necrosis factor receptors p75 and p55 in cerebrospinal fluid and plasma after traumatic brain injury. Shock. 2006, 26 (2): 122-127. 10.1097/01.shk.0000223127.41641.f4.PubMedGoogle Scholar
- Neumann H, Schweigreiter R, Yamashita T, Rosenkranz K, Wekerle H, Barde YA: Tumor necrosis factor inhibits neurite outgrowth and branching of hippocampal neurons by a rho-dependent mechanism. J Neurosci. 2002, 22 (3): 854-862.PubMedGoogle Scholar
- Williams AJ, Wei HH, Dave JR, Tortella FC: Acute and delayed neuroinflammatory response following experimental penetrating ballistic brain injury in the rat. J Neuroinflammation. 2007, 4: 17-10.1186/1742-2094-4-17.PubMedGoogle Scholar
- Bell MJ, Kochanek PM, Doughty LA, Carcillo JA, Adelson PD, Clark RS, Wisniewski SR, Whalen MJ, DeKosky ST: Interleukin-6 and interleukin-10 in cerebrospinal fluid after severe traumatic brain injury in children. J Neurotrauma. 1997, 14 (7): 451-457. 10.1089/neu.1997.14.451.PubMedGoogle Scholar
- Csuka E, Morganti-Kossmann MC, Lenzlinger PM, Joller H, Trentz O, Kossmann T: IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-alpha, TGF-beta1 and blood–brain barrier function. J Neuroimmunol. 1999, 101 (2): 211-221. 10.1016/S0165-5728(99)00148-4.PubMedGoogle Scholar
- Holmin S, Soderlund J, Biberfeld P, Mathiesen T: Intracerebral inflammation after human brain contusion. Neurosurgery. 1998, 42 (2): 291-298. 10.1097/00006123-199802000-00047. discussion 298–299PubMedGoogle Scholar
- McClain C, Cohen D, Phillips R, Ott L, Young B: Increased plasma and ventricular fluid interleukin-6 levels in patients with head injury. J Lab Clin Med. 1991, 118 (3): 225-231.PubMedGoogle Scholar
- Holmin S, Schalling M, Hojeberg B, Nordqvist AC, Skeftruna AK, Mathiesen T: Delayed cytokine expression in rat brain following experimental contusion. J Neurosurg. 1997, 86 (3): 493-504. 10.3171/jns.1997.86.3.0493.PubMedGoogle Scholar
- Knoblach SM, Fan L, Faden AI: Early neuronal expression of tumor necrosis factor-alpha after experimental brain injury contributes to neurological impairment. J Neuroimmunol. 1999, 95 (1–2): 115-125.PubMedGoogle Scholar
- Shohami E, Novikov M, Bass R, Yamin A, Gallily R: Closed head injury triggers early production of TNF alpha and IL-6 by brain tissue. J Cereb Blood Flow Metab. 1994, 14 (4): 615-619. 10.1038/jcbfm.1994.76.PubMedGoogle Scholar
- Stahel PF, Shohami E, Younis FM, Kariya K, Otto VI, Lenzlinger PM, Grosjean MB, Eugster HP, Trentz O, Kossmann T, others: Experimental closed head injury: analysis of neurological outcome, blood–brain barrier dysfunction, intracranial neutrophil infiltration, and neuronal cell death in mice deficient in genes for pro-inflammatory cytokines. J Cereb Blood Flow Metab. 2000, 20 (2): 369-380.PubMedGoogle Scholar
- Stover JF, Schoning B, Beyer TF, Woiciechowsky C, Unterberg AW: Temporal profile of cerebrospinal fluid glutamate, interleukin-6, and tumor necrosis factor-alpha in relation to brain edema and contusion following controlled cortical impact injury in rats. Neurosci Lett. 2000, 288 (1): 25-28. 10.1016/S0304-3940(00)01187-3.PubMedGoogle Scholar
- Scherbel U, Raghupathi R, Nakamura M, Saatman KE, Trojanowski JQ, Neugebauer E, Marino MW, McIntosh TK: Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury. Proc Natl Acad Sci U S A. 1999, 96 (15): 8721-8726. 10.1073/pnas.96.15.8721.PubMedGoogle Scholar
- Shohami E, Ginis I, Hallenbeck JM: Dual role of tumor necrosis factor alpha in brain injury. Cytokine Growth Factor Rev. 1999, 10 (2): 119-130. 10.1016/S1359-6101(99)00008-8. ReviewPubMedGoogle Scholar
- Oshima T, Lee S, Sato A, Oda S, Hirasawa H, Yamashita T: TNF-alpha contributes to axonal sprouting and functional recovery following traumatic brain injury. Brain Res. 2009, 1290: 102-110.PubMedGoogle Scholar
- Francis J, Chu Y, Johnson AK, Weiss RM, Felder RB: Acute myocardial infarction induces hypothalamic cytokine synthesis. Am J Physiol Heart Circ Physiol. 2004, 286 (6): H2264-H2271. 10.1152/ajpheart.01072.2003.PubMedGoogle Scholar
- Bao F, Fleming JC, Golshani R, Pearse DD, Kasabov L, Brown A, Weaver LC: A selective phosphodiesterase-4 inhibitor reduces leukocyte infiltration, oxidative processes, and tissue damage after spinal cord injury. J Neurotrauma. 2011, 28 (6): 1035-1049. 10.1089/neu.2010.1575.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.